Since 2013, BioPorto’s strategy has focused on commercializing the company’s diagnostic portfolio. With this strategy, we have laid the groundwork for accelerating the global roll-out of The NGAL Test™ which is expected to contribute significantly to our growth from 2016. BioPorto has been working on NGAL as a biomarker for years, during the course of which NGAL has transitioned from being a single antibody for research use only and in manually demanding ELISA kits, to its current use for automated testing in hospitals’ central laboratory systems where the response time has been reduced to 15 minutes. BioPorto’s other biomarker—MBL for analyzing immunodeficiencies—also started out as an antibody and, in its present ELISA format, is also turning out to have prospects of steadily increasing sales over a number of years. Concurrent with this commercial focus, we are using the cornerstone of our core business—our portfolio of antibodies and our ability to develop new antibodies—to select new markers assessed as having attractive potential.